According to filings with the U.S. Securities and Exchange Commission, LuminX Global is raising up to $8,000,000.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About LuminX Global
LuminX is a pioneering AI-driven company specializing in dental diagnostics. We are developing the LuminX Probe, a pre-FDA periodontal diagnostic platform that allows clinicians to objectively identify periodontal disease markers. LuminX brings together a multidisciplinary team of experts with extensive experience in medical device R&D, machine learning, dentistry, and business management. Supported by a world-class clinical advisory board of leading dental experts from the US and Israel and an experienced board of directors, our team is united by a shared goal: to set a new standard for dental care.

To learn more about LuminX Global, visit https://www.luminxsmile.com/
LuminX Global Linkedin Page: https://www.linkedin.com/company/luminx-smile/

Contact:
Harold Craig, Chief Executive Officer
513-703-2066
https://www.linkedin.com/in/waynecraig/

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.